<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201015</url>
  </required_header>
  <id_info>
    <org_study_id>277578</org_study_id>
    <nct_id>NCT04201015</nct_id>
  </id_info>
  <brief_title>Optimising Pacing for Contractility 2</brief_title>
  <acronym>OPT-cont 2</acronym>
  <official_title>Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have demonstrated that they can reliably identify an optimum heart rate&#xD;
      range for contractility of the left ventricle in patients with chronic heart failure (CHF).&#xD;
      They have also demonstrated in an acute cross-over and a small parallel group feasibility&#xD;
      study that keeping the heart rate in this range (versus standard rate-response programming)&#xD;
      in patients with CHF is associated with increased exercise time on a treadmill (around 60s or&#xD;
      10%). They now want to explore in a randomised, placebo-controlled 3-arm parallel group trial&#xD;
      whether optimal programming versus standard rate-response programming versus no rate-response&#xD;
      programming for 6 months leads to appreciable improvements in exercise time and quality of&#xD;
      life, while having no adverse effects on left ventricular function and battery longevity and&#xD;
      what the mechanisms of this might be.&#xD;
&#xD;
      360 patients with CHF and a pacemaker will undergo the non-invasive echocardiographic&#xD;
      assessment to establish the force frequency relationship and the optimal heart rate for&#xD;
      contractility. They will then perform a treadmill walk test, complete quality of life&#xD;
      questionnaires and be offered the opportunity to participate in a series of mechanistic&#xD;
      substudies. They will then be randomised to optimal rate-response settings, standard rate&#xD;
      response settings or no rate-response settings and followed up at 6 months at which point the&#xD;
      tests will be repeated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      Design: This will be a randomised, double-blind 'placebo' controlled trial of optimised&#xD;
      programming versus standard rate-response settings, aiming to determine whether the short&#xD;
      term improvements translate into longer term benefits.&#xD;
&#xD;
      Study participants: 360 adult patients (&gt;18years).&#xD;
&#xD;
      Study Procedures: Patients attending the heart failure clinic, the pacemaker clinic or&#xD;
      previous research participants will be approached with a standard letter and information&#xD;
      sheet and then a telephone call to make sure any remaining questions are answered.&#xD;
&#xD;
      Patients agreeing to participate will attend the clinical research facility (CRF) and will be&#xD;
      asked to sign a consent form. Each patient will have a standard device check, check of their&#xD;
      demographic data, and co-morbidities. The investigators will record a resting cardiac&#xD;
      ultrasound, and measure the force frequency relationship (FFR) to determine critical heart&#xD;
      rate (HR), and the optimal range of HR rise. All images will be stored for offline analysis.&#xD;
      Participants will then be asked to do a symptom-limited walk test on the treadmill (until&#xD;
      they cannot do any more). At this first visit, participants will also complete quality of&#xD;
      life questionnaires and be invited to participate in substudies including cardiac magnetic&#xD;
      resonance, blood tests, tests of autonomic dysfunction. All of these activities will take&#xD;
      place in the Clinical Research Facility at Leeds General Infirmary.&#xD;
&#xD;
      Randomisation: Each patient will then be randomised to either optimised programming (n=120)&#xD;
      as predicted by their force-frequency curve, standard settings (n=120) or no rate response&#xD;
      programming (n=120). In the optimised group, programming will keep heart rates below the&#xD;
      critical HR. Randomisation will be by a random number generator and programming will be&#xD;
      undertaken by one of my colleagues to maintain blinding.&#xD;
&#xD;
      Follow-up: Each patient will be called at one month to check that they are tolerating any&#xD;
      changes and will then be invited back at 6 months for a repeat resting echocardiogram,&#xD;
      treadmill walk test and quality of life assessment.&#xD;
&#xD;
      Data: All data will be stored on a bespoke Excel spreadsheet on an LTHT server in a&#xD;
      password-protected folder.&#xD;
&#xD;
      Primary Endpoint: The effects of heart rate programming that optimises heart rate for&#xD;
      contractility on change in treadmill-based walk distance over six months in patients with&#xD;
      heart failure and a pacemaker.&#xD;
&#xD;
      Secondary endpoints: 1) the safety of pacemaker programming optimised for heart rate in&#xD;
      patients with heart failure and a pacemaker, 2) the effect of this programming on change of&#xD;
      quality of life at 6 months 3) the effect of this programming on change in cardiac function&#xD;
      at 6 months.&#xD;
&#xD;
      Mechanistic endpoints: 1) The effect of heart rate programming on measures of autonomic&#xD;
      function, 2) Changes in cardiac function during exercise, 3) The effect of optimised heart&#xD;
      rate programming on strain, wall stress and perfusion by cardiac magnetic resonance, 4)&#xD;
      changes in biomarkers associated with heart failure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the technician doing the programming will know how the pacemaker has been set.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treadmill walk time</measure>
    <time_frame>6 months</time_frame>
    <description>Time walked during a standard incremental treadmill test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life 1</measure>
    <time_frame>6 months</time_frame>
    <description>EQ5D-5L score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 2</measure>
    <time_frame>6 months</time_frame>
    <description>KCCQ score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical composite score</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical outcomes combined (death, hospitalisation, NYHA symptom level, diuretic dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function during exercise measured by LVEF on echocardiogrpahy</measure>
    <time_frame>6 months</time_frame>
    <description>As assessed on a cycle ergometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall stress by cardiac MRI</measure>
    <time_frame>6 months</time_frame>
    <description>Wall stress assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Measures of Muscle Sympathetic Nerve Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Pacemaker</condition>
  <arm_group>
    <arm_group_label>Standard rate-response settings</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients allocated to standard rate-response settings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate-response settings off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients allocated to deactivated rate-response settings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized rate-response settings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to optimised rate-response settings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Heart rate optimisation using force frequency data</intervention_name>
    <description>Programming heart rate rise according to the force frequency relationship</description>
    <arm_group_label>Optimized rate-response settings</arm_group_label>
    <arm_group_label>Rate-response settings off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left ventricular systolic dysfunction (LVEF&lt;50%),&#xD;
&#xD;
          -  Cardiac pacemaker,&#xD;
&#xD;
          -  Able to perform a peak exercise test,&#xD;
&#xD;
          -  Willing and able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Angina pectoris symptoms limiting exercise tolerance,&#xD;
&#xD;
          -  Unstable heart failure symptoms (medical therapy changes in last three months), Poor&#xD;
             image quality,&#xD;
&#xD;
          -  Calcium channel blockers (CCBs).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klaus K Witte, MD</last_name>
    <phone>01133926642</phone>
    <email>k.k.witte@leeds.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus K Witte, MD</last_name>
      <email>k.k.witte@leeds.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Klaus K Witte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>KK Witte</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>after initial analysis</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

